Delcath(DCTH)
QUEENSBURY, NYPharmaceutical
Focus: Delcath is a specialty pharmaceutical company focused on hepatic delivery systems and oncology, with a public listing (NASDAQ: DCTH) and 1,001-5,000 employees. They commercialize HEPZATO (melphalan) and are advancing a pipeline of melphalan-based therapies for liver cancers and ocular melanoma.
Profile data last refreshed 18h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
1001-5000
Open Jobs
0
About Delcath
AI assessmentNot HiringNo open roles listed right now. Follow Delcath to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Delcath's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$37M
Key Products
Growth8.0yr
Help build intelligence for Delcath
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.